BETA DRUGS
Beta Drugs Share Price
Beta Drugs Performance
Day Range
- Low
- High
52 Week Range
- Low
- High
- Open Price
- Previous Close
- Volume
Start SIP in BETA DRUGS
Start SIPBeta Drugs Investment Rating
-
Master Rating:
-
Beta Drugs has an operating revenue of Rs. 456.69 Cr. on a trailing 12-month basis. An annual revenue growth of 58% is outstanding, Pre-tax margin of 19% is great, ROE of 26% is exceptional. The company has a reasonable debt to equity of 13%, which signals a healthy balance sheet. The stock from a technical standpoint is trading close to its 50DMA and comfortably placed above its 200DMA, around 13% above 200DMA. It needs to take support around the 50 DMA level to continue further upside move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 75 which is a FAIR score but needs to improve its earnings, a RS Rating of 75 which is FAIR indicating the recent price performance, Buyer Demand at D+ which indicates heavy supply, Group Rank of 125 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of B is close to being the best. Institutional holding has remained stable in the last reported quarter. Overall, the stock definitely has some strength, you may want to examine it in more detail.
EPS Strength
Price Strength
Buyer Demand
Group Rank
| Indicator |
|---|
| Oper Rev Qtr Cr |
| Operating Expenses Qtr Cr |
| Operating Profit Qtr Cr |
| Depreciation Qtr Cr |
| Interest Qtr Cr |
| Tax Qtr Cr |
| Net Profit Qtr Cr |
Beta Drugs Technicals
EMA & SMA
- Bullish Moving Average
- ___
- 0
- Bearish Moving Average
- ___
- 0
- 20 Day
- 787.42
- 50 Day
- 782.97
- 100 Day
- 759.69
- 200 Day
- 697.39
- 20 Day
- 789
- 50 Day
- 795.63
- 100 Day
- 785.61
- 200 Day
- 697.34
Beta Drugs Resistance and Support
| Resistance | |
|---|---|
| First Resistance | 807 |
| Second Resistance | 826 |
| Third Resistance | 853.05 |
| RSI | 47.07 |
| MFI | 36.43 |
| MACD Single Line | -0.7 |
| MACD | -3.22 |
| Support | |
|---|---|
| First Resistance | 760.95 |
| Second Resistance | 733.9 |
| Third Resistance | 714.9 |
Beta Drugs Delivery and Volume
| Period | NSE + BSE Volume Avg | NSE + BSE Delivery Volume Avg | NSE + BSE Delivery Volume % |
|---|---|---|---|
| Day | 2,600 | 179,998 | 69.23 |
| Week | 5,160 | 431,995 | 83.72 |
| 1 Month | 4,219 | 353,345 | 83.75 |
| 6 Month | 7,048 | 536,535 | 76.13 |
Beta Drugs Result Highlights
Beta Drugs Synopsis
NSE-Medical-Diversified
Beta Drugs is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 124.85 Cr. and Equity Capital is Rs. 9.61 Cr. for the Year ended 31/03/2022. Beta Drugs Ltd. is a Public Limited Listed company incorporated on 21/09/2015 and has its registered office in the State of Himachal Pradesh, India. Company’s Corporate Identification Number(CIN) is L24230HP2005PLC028969 and registration number is 028969.| Market Cap | 749 |
| Sales | 125 |
| Shares in Float | 0.32 |
| No of funds | 1 |
| Yield |
| Book Value | 9.67 |
| U/D Vol ratio | 0.7 |
| LTDebt / Equity | 7 |
| Alpha | 0.3 |
| Beta | 0.93 |
Beta Drugs
| Owner Name | Jun-22 | Mar-22 | Dec-21 | Sep-21 |
|---|---|---|---|---|
| Promoters | 66.71% | 66.71% | 66.71% | |
| Foreign Portfolio Investors | 0.29% | 0.29% | 0.29% | |
| Others | 33% | 33% | 33% |
Beta Drugs Management
| Name | Designation |
|---|---|
| Mr. Rahul Batra | Chairman & Managing Director |
| Mr. Varun Batra | Joint Managing Director |
| Mr. Balwant Singh | Whole Time Director |
| Mrs. Seema Chopra | Whole Time Director |
| Mr. Manmohan Khanna | Independent Director |
| Mr. Rohit Parti | Independent Director |
Beta Drugs Forecast
Price Estimates
Beta Drugs Corporate Action
| Date | Purpose | Remarks |
|---|---|---|
| 2022-04-27 | Audited Results | |
| 2021-10-25 | Quarterly Results | |
| 2021-04-27 | Audited Results | |
| 2020-10-19 | Quarterly Results | |
| 2020-06-17 | Others | To consider Fund Raising |
Beta Drugs FAQs
What is Share Price of Beta Drugs ?
Beta Drugs share price is ₹779 As on 30 September, 2022 | 03:11
What is the Market Cap of Beta Drugs ?
The Market Cap of Beta Drugs is ₹748.9 Cr As on 30 September, 2022 | 03:11
What is the P/E ratio of Beta Drugs ?
The P/E ratio of Beta Drugs is As on 30 September, 2022 | 03:11
What is the PB ratio of Beta Drugs ?
The PB ratio of Beta Drugs is 8.1 As on 30 September, 2022 | 03:11